Fiasp is already for sale in EU and Canada. Where is Afrezz?
Oct 28, 2017 12:47:15 GMT -5
via mobile
sla55 and compound26 like this
Post by lakers on Oct 28, 2017 12:47:15 GMT -5
By Sysy Morales September 29th, 2017
Novo Nordisk’s Fiasp (insulin aspart) 100 Units/mL has been approved by the US FDA.
Fiasp is a fast-acting mealtime insulin for adults with type 1 and type 2 diabetes. According to a PR Newswire press release, it can be given at the beginning of a meal or within 20 minutes after starting a meal.
Fiasp is a new formulation of NovoLog. They added niacinamide, otherwise known as vitamin B3 which speeds up the rate of initial absorption. Customers in Europe and Canada have already been using it.
How Fast is Insulin Fiasp?
The new insulin Fiasp starts working in about 2.5 minutes and will be available by FlexTouch insulin pens or via a 10mL vial.
Currently, most fast-acting insulin such as Humalog and NovoLog need 10-15 minutes to begin working and while this doesn’t seem like a big difference, it can be for those who want to begin lowering blood sugar as soon as possible or those who don’t want to wait so long (or at all) before eating for their insulin to kick in.
Bruce Bode, MD FACE and President of Atlanta Diabetes Associates and Associate Professor at Emory University School of Medicine said in a statement:
“With Fiasp, we’ve built on the insulin aspart molecule to create a new treatment option to help patients meet their post-meal blood sugar target,” and that “The intention of rapid acting insulin therapy is to mimic, as much as possible, the natural physiological insulin response that occurs after meals, a process that is important for optimal A1C management.”
Fiasp has been FDA approved thanks to results from the onset phase 3a clinical development program. These trials involved over 2,000 adults with type 1 and 2 diabetes. Participants showed a reduction in their A1c levels while taking Fiasp at mealtime and also after starting a meal.
Common adverse reactions, aside from low blood sugar episodes, were seen in ≥5% of the participants and included nasopharyngitis, upper respiratory tract infection, nausea, diarrhea and back pain.
How Much Will Fiasp Cost and When Can We Get It?
Fiasp is going to launch at the same list price as NovoLog and Novo Nordisk will be offering a Savings Card program for those who are eligible and have commercial insurance to reduce co-pays. Patients using the Novo Nordisk Patient Assistance Program will also have Fiasp available. If you want to learn more about that assistance program you can call 866-310-7549.
A representative for Novo Nordisk wrote in an email that we should see Fiasp available in US pharmacies in late December or by early 2018.
www.diabetesdaily.com/blog/new-ultra-fast-acting-insulin-fiasp-is-us-fda-approved-489794/
Novo Nordisk’s Fiasp (insulin aspart) 100 Units/mL has been approved by the US FDA.
Fiasp is a fast-acting mealtime insulin for adults with type 1 and type 2 diabetes. According to a PR Newswire press release, it can be given at the beginning of a meal or within 20 minutes after starting a meal.
Fiasp is a new formulation of NovoLog. They added niacinamide, otherwise known as vitamin B3 which speeds up the rate of initial absorption. Customers in Europe and Canada have already been using it.
How Fast is Insulin Fiasp?
The new insulin Fiasp starts working in about 2.5 minutes and will be available by FlexTouch insulin pens or via a 10mL vial.
Currently, most fast-acting insulin such as Humalog and NovoLog need 10-15 minutes to begin working and while this doesn’t seem like a big difference, it can be for those who want to begin lowering blood sugar as soon as possible or those who don’t want to wait so long (or at all) before eating for their insulin to kick in.
Bruce Bode, MD FACE and President of Atlanta Diabetes Associates and Associate Professor at Emory University School of Medicine said in a statement:
“With Fiasp, we’ve built on the insulin aspart molecule to create a new treatment option to help patients meet their post-meal blood sugar target,” and that “The intention of rapid acting insulin therapy is to mimic, as much as possible, the natural physiological insulin response that occurs after meals, a process that is important for optimal A1C management.”
Fiasp has been FDA approved thanks to results from the onset phase 3a clinical development program. These trials involved over 2,000 adults with type 1 and 2 diabetes. Participants showed a reduction in their A1c levels while taking Fiasp at mealtime and also after starting a meal.
Common adverse reactions, aside from low blood sugar episodes, were seen in ≥5% of the participants and included nasopharyngitis, upper respiratory tract infection, nausea, diarrhea and back pain.
How Much Will Fiasp Cost and When Can We Get It?
Fiasp is going to launch at the same list price as NovoLog and Novo Nordisk will be offering a Savings Card program for those who are eligible and have commercial insurance to reduce co-pays. Patients using the Novo Nordisk Patient Assistance Program will also have Fiasp available. If you want to learn more about that assistance program you can call 866-310-7549.
A representative for Novo Nordisk wrote in an email that we should see Fiasp available in US pharmacies in late December or by early 2018.
www.diabetesdaily.com/blog/new-ultra-fast-acting-insulin-fiasp-is-us-fda-approved-489794/